Sernova (TSE:SVA) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sernova Corp., a clinical-stage biotech company, has announced an oversubscribed private placement offering, receiving $4.7M in binding agreements against its offer of $4M. The investment, which is subject to TSX approval, indicates strong investor confidence in the company’s innovative Cell Pouch System platform aimed at treating chronic diseases like diabetes and thyroid disease.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.